Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

metabolic disorders

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (3) 17β-HSD (18) 5-HT Receptor (1) Acyltransferase (2) AMPK (2) Apoptosis (6) Autophagy (8) Btk (1) Calcium Channel (1) Cannabinoid Receptor (2) Casein Kinase (3) Caspase (1) COMT (5) COX (1) Cytochrome P450 (1) DNA Methyltransferase (1) Dopamine Receptor (2) Endogenous Metabolite (14) Estrogen Receptor/ERR (2) FAAH (1) FXR (3) GCGR (1) GLP Receptor (2) Glucosidase (1) GPR119 (1) HDAC (3) HIF/HIF Prolyl-Hydroxylase (1) HIV (3) HSV (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Isotope-Labeled Compounds (7) MAGL (1) Mitophagy (3) MMP (1) NAMPT (1) Notch (3) Organoid (2) Parasite (1) Phosphodiesterase (PDE) (1) PI5P4K (1) PPAR (4) Proton Pump (3) RAR/RXR (1) Reactive Oxygen Species (1) REV-ERB (1) ROR (1) SARS-CoV (3) SGLT (1) Transthyretin (TTR) (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (4) Endocrinology (1) Infection (7) Inflammation/Immunology (14) Metabolic Disease (75) Neurological Disease (21)

By Targets:

11β-HSD (3)

17β-HSD (18)

5-HT Receptor (1)

Acyltransferase (2)

AMPK (2)

Apoptosis (6)

Autophagy (8)

Btk (1)

Calcium Channel (1)

Cannabinoid Receptor (2)

Casein Kinase (3)

Caspase (1)

COMT (5)

COX (1)

Cytochrome P450 (1)

DNA Methyltransferase (1)

Dopamine Receptor (2)

Endogenous Metabolite (14)

Estrogen Receptor/ERR (2)

FAAH (1)

FXR (3)

GCGR (1)

GLP Receptor (2)

Glucosidase (1)

GPR119 (1)

HDAC (3)

HIF/HIF Prolyl-Hydroxylase (1)

HIV (3)

HSV (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Influenza Virus (1)

Isotope-Labeled Compounds (7)

MAGL (1)

Mitophagy (3)

MMP (1)

NAMPT (1)

Notch (3)

Organoid (2)

Parasite (1)

Phosphodiesterase (PDE) (1)

PI5P4K (1)

PPAR (4)

Proton Pump (3)

RAR/RXR (1)

Reactive Oxygen Species (1)

REV-ERB (1)

ROR (1)

SARS-CoV (3)

SGLT (1)

Transthyretin (TTR) (1)

Xanthine Oxidase (1)

By Research Areas:

Cancer (22)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (7)

Inflammation/Immunology (14)

Metabolic Disease (75)

Neurological Disease (21)

101

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153759

CRX000227

PPAR Metabolic Disease

CRX000227 is a PPAR modulator. CRX000227 can be used for research of metabolic or cell proliferative disorders .

CRX000227	PPAR	Metabolic Disease
CRX000227 is a PPAR modulator. CRX000227 can be used for research of metabolic or cell proliferative disorders .

HY-110178

WWL123	MAGL	Inflammation/Immunology
WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .

HY-156527

PHD-IN-2	HIF/HIF Prolyl-Hydroxylase	Cancer
PHD-IN-2 (Compound 91) is a PHD antagonist (IC₅₀: < 5 nM). PHD-IN-2 induces erythropoietin synthesis in HEP3B cells (EC₅₀: <2.5 μM). PHD-IN-2 can be used for research of cardiovascular disorders, metabolic disorders, hematological disorders, pulmonary disorders, kidney disorders, liver disorders, wound healing disorders, and cancer .

HY-147049

PAL-4	Others	Metabolic Disease
PAL-4 (compound 4) is a potent, selective and reversible Lysophospholipase-like 1 (LYPLAL1) activator with EC₅₀ value of 0.39 μM and 0.49 μM for mice LYPLAL1 and huamn LYPLAL1, respectively. PAL-4 can be used for researching metabolic disorders .

HY-160168

BTK-IN-31	Btk	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .

HY-133556

IQZ23	AMPK	Metabolic Disease
IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC₅₀=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders .

HY-117516

SR10067	REV-ERB	Neurological Disease Metabolic Disease
SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC₅₀ values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders .

HY-153476

GIP/GLP-1 dual receptor agonist-1	GCGR	Metabolic Disease
GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .

HY-103462

TC-F2	FAAH	Metabolic Disease Inflammation/Immunology Cancer
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .

HY-146731

PPARγ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .

HY-N8466

(-)-Lyoniresinol 9'-O-glucoside	Reactive Oxygen Species	Metabolic Disease
(-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .

HY-132205

DS45500853	Estrogen Receptor/ERR	Metabolic Disease
DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC₅₀ value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .

HY-14280

Entacapone 4 Publications Verification	COMT	Neurological Disease Cancer
Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC₅₀ values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC₅₀s>50 µM). Entacapone can be used for the research of Parkinson's disease . Entacapone serves as a inhibitor of FTO demethylation with an IC₅₀ of 3.5 μM, can be used for the research of metabolic disorders .

HY-144827

AM8936	Cannabinoid Receptor	Neurological Disease Metabolic Disease
AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC₅₀s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with K_i of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc .

HY-149663

BMS-986172	Acyltransferase	Metabolic Disease
BMS-986172 is an orally active, highly selective MGAT2 inhibitor with an IC₅₀ of 4.6 nM and 20 nM for hMGAT2 and mMGAT2, respectively. BMS-986172 has a T_1/2>120 min in vitro assays. BMS-986172 reduces food intake and body weight. BMS-986172 has the potential for metabolic disorders such as obesity and NASH research .

HY-14280A

Entacapone sodium salt	COMT	Neurological Disease
Entacapone sodium salt is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone sodium salt inhibits COMT from rat brain, erythrocytes and liver with IC₅₀ values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone sodium salt is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC₅₀s>50 µM). Entacapone sodium salt can be used for the research of Parkinson's disease . Entacapone sodium salt serves as as a inhibit of FTO demethylation with an IC₅₀ of 3.5 μM, can be used for the research of metabolic disorders .

HY-B1268

Docusate Sodium 1 Publications Verification Dioctyl sulfosuccinate sodium salt	HSV	Others
Docusate Sodium (Dioctyl sulfosuccinate sodium salt) is one of the main components in stool softeners. Docusate Sodium is a sulfated surfactant and may inactivate viral pathogens by disrupting viral envelopes and/or denaturing/disassociating proteins. Docusate Sodium is effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2. Docusate Sodium is an obesogen. Docusate Sodium with developmental exposure leads to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet in mice .

HY-143201

DS20362725	Estrogen Receptor/ERR	Metabolic Disease
DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC₅₀ value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .

HY-U00397

CB1 antagonist 1	Cannabinoid Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
CB1 antagonist 1 is an antagonist of CB1 receptor, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.

HY-148104

ACSS2-IN-2	Others	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC₅₀ value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .

HY-153530

LI-2242	Others	Neurological Disease Metabolic Disease
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC₅₀ values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .

HY-113107

3-Hydroxydodecanoic acid

Endogenous Metabolite Metabolic Disease

3-Hydroxydodecanoic acid is a medium-chain fatty acid associated with fatty acid metabolic disorders.

3-Hydroxydodecanoic acid	Endogenous Metabolite	Metabolic Disease
3-Hydroxydodecanoic acid is a medium-chain fatty acid associated with fatty acid metabolic disorders.

HY-N9275

Isopicropodophyllin	Others	Metabolic Disease Inflammation/Immunology
Isopicropodophyllin is a natural compound that can be used for metabolic or chronic inflammatory disorder research .

HY-109167

Aramisulpride R-(+)-Amisulpride	Dopamine Receptor	Neurological Disease
Aramisulpride is a dopamine D2 receptor and serotonin receptor antagonist used for the research of metabolic disorders .

HY-132924

BMS-963272

Acyltransferase Metabolic Disease

BMS-963272 is a potent, selective MGAT2 inhibitor (IC₅₀ = 7.1 nM) for the research of metabolic disorders.
HY-147627

GLP-1R agonist 14

GLP Receptor Metabolic Disease

GLP-1R agonist 14 (Compound 14) is a GLP-1 receptor agonist with an EC₅₀ of 0-20 nM against h-GLP-1 .

BMS-963272	Acyltransferase	Metabolic Disease
BMS-963272 is a potent, selective MGAT2 inhibitor (IC₅₀ = 7.1 nM) for the research of metabolic disorders.

GLP-1R agonist 14	GLP Receptor	Metabolic Disease
GLP-1R agonist 14 (Compound 14) is a GLP-1 receptor agonist with an EC₅₀ of 0-20 nM against h-GLP-1 .

HY-111327

Valibose	Glucosidase	Metabolic Disease
Valibose is analpha-glucosidaseinhibitor, and ameliorates the metabolic disorder of glucose and lipids and the nephropathy in Streptozotocin (HY-13753)-induced diabetic rats .

HY-153525

FXR agonist 5	FXR	Metabolic Disease Inflammation/Immunology
FXR agonist 5 (compound 1) is a FXR agonist. FXR agonist 5 can be used for research in diseases or disorders caused by metabolic inflammation .

HY-113288

Campestanol	Others	Metabolic Disease
Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders .

HY-114392

Gly-β-MCA 10+ Cited Publications	FXR Autophagy	Metabolic Disease
Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders .

HY-101455

CDN1163 5+ Cited Publications	Calcium Channel	Metabolic Disease
CDN1163 is an allosteric sarco/endoplasmic reticulum Ca ²⁺-ATPase (SERCA) activator that improves Ca ²⁺ homeostasis. CDN1163 attenuates diabetes and metabolic disorders .

HY-12813

PDE10-IN-1

Phosphodiesterase (PDE) Neurological Disease

PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.

PDE10-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.

HY-113013

Hydroxypyruvic acid β-Hydroxypyruvic acid; 3-Hydroxypyruvic acid	Endogenous Metabolite	Metabolic Disease
Hydroxypyruvic acid (β-Hydroxypyruvic acid) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.

HY-N5134

5'-Guanylic acid 1 Publications Verification 5'-GMP; 5'-guanosine monophosphate	Endogenous Metabolite	Metabolic Disease
5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-154867

DNMT2-IN-1	DNA Methyltransferase	Cancer
DNMT2-IN-1 (compound 80) is a potent and selective DNMT2 (DNA methyltransferase 2) inhibitor with an IC₅₀ value of 1.2 μM, and has the potential for mental and metabolic disorders or cancer research .

HY-N9246

4'-Methoxyflavanone	Others	Others
4'-Methoxyflavanone is a flavonoid compound. 4'-Methoxyflavanone is isolated from the natural Isaria fumosorosea KCH J2. 4'-Methoxyflavanone regulates metabolic disorders, prevents cardiovascular disease and protects neurons .

HY-101036

Choline bitartrate 2 Publications Verification
Choline bitartrate is a vitamin-like essential nutrient, can affect diseases such as liver disease, atherosclerosis and neurological disorders . Choline bitartrate is a precursor for the neurotransmitter acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism .

HY-A0213

Tiludronate Tiludronic acid
Tiludronate (Tiludronic Acid), an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties .

HY-A0213A

Tiludronate disodium Tiludronic acid disodium	Proton Pump	Inflammation/Immunology
Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties .

HY-113013A

Hydroxypyruvic acid lithium hydrate β-Hydroxypyruvic acid lithium hydrate; 3-Hydroxypyruvic acid lithium hydrate	Endogenous Metabolite	Metabolic Disease
Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.

HY-N0035

Arctigenin 5+ Cited Publications (-)-Arctigenin	MMP Influenza Virus Autophagy Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .

HY-A0213B

Tiludronate disodium hemihydrate Tiludronic acid disodium hemihydrate	Proton Pump	Metabolic Disease
Tiludronate (Tiludronic Acid) disodium hemihydrate, an orally active bisphosphonate, can act an osteoregulator. Tiludronate disodium hemihydrate is used for the research of the metabolic bone disorders. Tiludronate disodium hemihydrate is a potent inhibitor of the osteoclast vacuolar H ⁺-ATPase. Antiresorptive and anti-inflammatory properties .

HY-156968

GLP-1 receptor agonist 14	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 14 (compound 73) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 14 plays an important role in diabetes or other metabolic disorders .

HY-112528

Glycerophospho-N-palmitoyl ethanolamine GP-NPEA	Others	Metabolic Disease
Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is a metabolic precursor of palmitoyl ethanolamide PEA (HY-157829). Glycerophospho-N-palmitoyl ethanolamine decreases in the cortex of CUMS rats, which may be related to a disorder in the endocannabinoid system arising after the onset of depression .

HY-W013136

Triheptanoin UX007	Others	Neurological Disease
Triheptanoin (Propane-1,2,3-triyl triheptanoate) is a synthetic medium-chain triglyceride (MCT) consisting of three odd-chain 7-carbon (heptanoate) fatty acids on a glycerol backbone. Triheptanoin can be used for the research of inherited metabolic disorders .

HY-128790S1

4-Methoxyestrone-13C6	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
4-Methoxyestrone- ¹³C₆ is a ¹³C-labeled 5'-Guanylic acid. 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and

HY-W016145

L-Glutamic acid monosodium (hydrate)	Apoptosis	Metabolic Disease Cancer
L-Glutamic acid monosodium hydrate is a nutritional additive and flavoring agent. L-Glutamic acid monosodium hydrate can reduce obesity and induce metabolic disorders associated with oxidative stress. L-Glutamic acid monosodium hydrate induces oxidative stress,DNA damage and apoptosis in the liver and brain tissues of mice .

HY-115688A

(S)-TXNIP-IN-1 1 Publications Verification	Others	Others
(S)-TXNIP-IN-1 is the less active S-enantiomer of TXNIP-IN-1 (HY-115688). TXNIP-IN-1 is a TXNIP-TRX complex inhibitor which can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease

HY-115688

TXNIP-IN-1 1 Publications Verification	Others	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
TXNIP-IN-1 is TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex inhibitor extracted from patent US20200085800A1, Compound 1. TXNIP-IN-1 can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease .

HY-A0213AS

Tiludronate-d5 sodium Tiludronic acid-d₅ (sodium)	Proton Pump	Inflammation/Immunology
Tiludronate-d₅ (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].

Cat. No.	Product Name

HY-L059

Pyroptosis Compound Library

1256 compounds

Programmed cell death pathways, including apoptosis, pyroptosis and necroptosis, are regulated by unique sets of host proteins that coordinate a variety of biological outcomes. Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is likely to form part of the antimicrobial response. This process promotes the rapid clearance of various bacterial, viral, fungal and protozoan infections by removing intracellular replication niches and enhancing the host's defensive responses. Pyroptosis has been widely studied in inflammatory and infection disease models. Recently, there are growing evidences that pyroptosis also plays an important role in the development of cancer, cardiovascular diseases and Metabolic disorder, etc.

MCE designs a unique collection of 1256 pyroptosis-related compounds mainly focusing on the key targets in the pyroptosis signaling pathway and can be used in the research of pyroptosis signal pathway and related diseases.

HY-L046

Anti-Cardiovascular Disease Compound Library

1393 compounds

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.

MCE supplies a unique collection of 1393 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

HY-L175

Inflammasomes related Compound Library

67 compounds

Inflammasomes are classic pattern recognition receptors for natural immune responses. Inflammasomes are polymeric protein complexes that regulate inflammatory responses and pyrolytic cell death, thereby exerting the host's defense against microorganisms. Inflammasomes sensors are associated with adapter proteins, activating inflammatory caspase-1, releasing inflammatory cytokines and inducing cell death, endowing the host with defense against pathogens. NLRP1, NLRP3, NLRC4, AIM2, and pyrin are considered typical inflammasomes because they convert cysteine asparaginase-1 into catalytically active capsaicin-1. In addition to infectious diseases, the importance of inflammasomes is also related to various clinical diseases, such as autoimmune diseases, neurodegeneration and metabolic disorders, and the development of cancer. Therefore, it is necessary to strictly regulate the activation and function of inflammasomes to avoid accidental host tissue damage while inducing pathogens to kill the inflammatory response.

MCE designs a unique collection of 67 inflammasomes related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

HY-L040

Anti-diabetic Compound Library

740 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 740 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113107

3-Hydroxydodecanoic acid	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
3-Hydroxydodecanoic acid is a medium-chain fatty acid associated with fatty acid metabolic disorders.

HY-113013

Hydroxypyruvic acid β-Hydroxypyruvic acid; 3-Hydroxypyruvic acid	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Hydroxypyruvic acid (β-Hydroxypyruvic acid) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.

HY-N5134

5'-Guanylic acid 1 Publications Verification 5'-GMP; 5'-guanosine monophosphate	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N8466

(-)-Lyoniresinol 9'-O-glucoside	Structural Classification Albizia julibrissin Durazz. Leguminosae Source classification Plants Saccharides Monosaccharides	Reactive Oxygen Species
(-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .

HY-N9275

Isopicropodophyllin	Structural Classification Natural Products Classification of Application Fields Source classification Centaurea ornata Plants Umbelliferae Inflammation/Immunology Disease Research Fields	Others
Isopicropodophyllin is a natural compound that can be used for metabolic or chronic inflammatory disorder research .

HY-N9246

4'-Methoxyflavanone	Structural Classification Flavonoids Microorganisms Flavonones Source classification	Others
4'-Methoxyflavanone is a flavonoid compound. 4'-Methoxyflavanone is isolated from the natural Isaria fumosorosea KCH J2. 4'-Methoxyflavanone regulates metabolic disorders, prevents cardiovascular disease and protects neurons .

HY-113013A

Hydroxypyruvic acid lithium hydrate β-Hydroxypyruvic acid lithium hydrate; 3-Hydroxypyruvic acid lithium hydrate	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.

HY-N0035

Arctigenin 5+ Cited Publications (-)-Arctigenin	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Source classification Lignans Metabolic Disease Plants Compositae Caesalpinia magnifoliolata Metc. Endogenous metabolite Infection Human Gut Microbiota Metabolites Phenylpropanoids Inflammation/Immunology Disease Research Fields Cancer	MMP Influenza Virus Autophagy Apoptosis
Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .

HY-116003

12,13-DiHOME	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
12,13-DiHOME is a stimulator of Brown adipose tissue (BAT), as well as a thermogenic lipokine that activates BAT in response to cold. (±)12,13-DiHOME activates BAT fuel uptake and enhances cold tolerance, via promoting the translocation of the FA transporters FATP1 and CD36 to the cell membrane. (±)12,13-DiHOME can be used for research of metabolic disorders .

HY-10585A

Valproic acid sodium Maximum Cited Publications 33 Publications Verification Sodium Valproate sodium	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585

Valproic acid Maximum Cited Publications 33 Publications Verification Dipropylacetic Acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585B

Valproic acid (sodium)(2:1) VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-14393

Emodin 15+ Cited Publications Frangula emodin	Structural Classification Classification of Application Fields Polygonaceae Source classification Plants Endogenous metabolite Quinones Human Gut Microbiota Metabolites Microorganisms Rheum palmatum L. Anthraquinones Phenols Polyphenols Disease Research Fields Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-N11507

Tibesaikosaponin V TKV	Triterpenes Structural Classification Terpenoids Source classification Plants Umbelliferae	PPAR
Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders .

HY-14393R

Emodin (Standard) Frangula emodin (Standard)	Quinones Structural Classification Classification of Application Fields Rheum palmatum L. Polygonaceae Source classification Phenols Plants Disease Research Fields Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Standard) is the analytical standard of Emodin. This product is intended for research and analytical applications. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-N1957

Gamma-Mangostin 1 Publications Verification γ-Mangostin	Structural Classification Xanthones Classification of Application Fields Guttiferae Phenols Polyphenols Garcinia mangostana Linn. Metabolic Disease Plants Disease Research Fields	5-HT Receptor COX Transthyretin (TTR)
Gamma-Mangostin is a novel competitive 5-hydroxytryptamine 2A (5-HT2A) receptor antagonist and potent epoxidase 2 (COX-2) inhibitor, as well as a transthyroxin protein (TTR) profibrosis inhibitor. Gamma-Mangostin binds to the thyroxine (T4)-binding sites and stabilized the TTR tetramer . Gamma-Mangostin inhibits [3 ^H] spiperone binding to cultured rat aortic myocytes (IC₅₀=3.5 nM) and reduces The perfusion pressure response of rat coronary artery to 5-HT2A (IC₅₀=0.32 μM). Gamma-Mangostin has anti-inflammatory, antibacterial, antioxidant and anticancer activities, and can be used in the study of metabolic disorders such as diabetes .

Cat. No.	Product Name	Chemical Structure

HY-14280S

Entacapone-d10

Entacapone-d₁₀ is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

HY-128790S1

4-Methoxyestrone-13C6
4-Methoxyestrone- ¹³C₆ is a ¹³C-labeled 5'-Guanylic acid. 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and

HY-A0213AS

Tiludronate-d5 sodium
Tiludronate-d₅ (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].

HY-14280S2

(E)-Entacapone-d10

(E)-Entacapone-d₁₀ is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

HY-N5134S1

5'-Guanylic acid-13C10 dilithium

5'-Guanylic acid- ¹³C₁₀ (5'-GMP- ¹³C₁₀ dilithium; 5'-guanosine monophosphate- ¹³C₁₀) dilithium is ¹³C-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S2

5'-Guanylic acid-15N5 dilithium
5'-Guanylic acid- ¹⁵N₅ (5'-GMP- ¹⁵N₅ dilithium; 5'-guanosine monophosphate- ¹⁵N₅) dilithium is ¹⁵N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S3

5'-Guanylic acid-d12 dilithium
5'-Guanylic acid-d₁₂ (5'-GMP-d₁₂ dilithium; 5'-guanosine monophosphate-d₁₂) dilithium is deuterium labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S5

5'-Guanylic acid-13C10,15N5 dilithium

5'-Guanylic acid- ¹³C₁₀, ¹⁵N₅ (5'-GMP- ¹³C₁₀, ¹⁵N₅ dilithium; 5'-guanosine monophosphate- ¹³C₁₀, ¹⁵N₅) dilithium is ¹³C and ¹⁵N-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-14393S

Emodin-d4

Emodin-d₄ is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].

HY-N5134S4

5'-Guanylic acid-15N5,d12 dilithium

5'-Guanylic acid- ¹⁵N₅,d₁₂ (5'-GMP- ¹⁵N₅,d₁₂ dilithium; 5'-guanosine monophosphate- ¹⁵N₅,d₁₂) dilithium is deuterium and ¹⁵N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks